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Introduction
Early-onset/juvenile ataxia is usually a challenging diagnosis due to 
significant clinical overlap. Here, we discuss the utility of  alpha-fetopro-
tein (AFP) for the investigation of  ataxia syndromes associated with poly-
neuropathy and hyperkinesias such as chorea and dystonia. First, we 
describe a patient featuring the clinical and laboratory signs of  ataxia with 
oculomotor apraxia 2 (AOA2). We use this case as a platform to discuss 
diagnostic issues, review the literature, and the limitations of  AFP as a 
biomarker for disease progression.
Case presentation
A Swedish 29-year-old woman, born to nonconsanguineous healthy 
parents, was referred to our center for evaluation. There was no family 
history of  neurological disease. At age 5, the patient’s parents noticed mild 
clumsiness but the patient was able to participate in sporting activities. 
However, marked worsening occurred during early puberty, affecting her 
balance, and both slurred speech and diplopia appeared at this point. 
From age 15, the patient was evaluated at other hospitals, and those inves-
tigations revealed axonal sensorimotor polyneuropathy and cerebellar 
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Abstract
Background: Ataxias represent a challenging group of  disorders due to significant clinical overlap. Here, we present a patient with early-onset progressive ataxia, 
polyneuropathy and discuss how elevation of  alpha fetoprotein (AFP) narrows the differential diagnosis.
Case report: Ataxia, polyneuropathy, and mild elevation of  AFP are features compatible with ataxia with oculomotor apraxia type 2 (AOA2) but also with ataxia 
with oculomotor apraxia type 4 (AOA4). A genetic analysis demonstrated biallelic mutations in senataxin (SETX ), confirming the diagnosis of  AOA2.
Discussion: Mild elevation of  AFP is found in patients with AOA2 and AOA4, and higher levels are commonly seen in ataxia-telangiectasia. AFP is a useful diag-
nostic tool but not a biomarker for disease progression in AOA2.
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atrophy. However, no etiological diagnosis was established. Diplopia was 
caused by strabismus and was treated at age 21 with prism lenses and at 
26 with surgery. However, these surgeries had transient benefit only. 
There was no indication of  cognitive deficits, and the patient finished 
her training as a laboratory technician and has worked full time for 
some years. The patient has become dependent on a walker, and an 
electric wheelchair for longer distances. Due to this progression, the 
patient has only worked part-time during the last 2 years. During the 
last 3 years, she has experienced recurrent paresthesias in both legs. 
There was no indication of  premature ovarian failure (POF). Follicle-
stimulating hormone and luteinizing hormone levels were normal.
At age 27 years, the patient’s examination was characterized by pre-
dominant axial ataxia, mild dysarthria, and dysmetria. At this point, her 
scale for the assessment and rating of  ataxia (SARA) score was 12.5 
(range 0–40, normal 0–3). Oculomotor apraxia (OMA) was absent but 
broken smooth pursuit and nystagmus were evident, and both her con-
vergence and optokinetic nystagmus (OKN) were impaired. The rest of  
the examination demonstrated areflexia, but pyramidal signs, other 
movement disorders, muscle atrophy, and telangiectasias were absent. 
Two years later her SARA score was 15.5 and her functional stage on 
the Friedreich ataxia (FRDA) rating scale was 4 (range 0–6), corre-
sponding to moderate disability. The main features of  the examination 
are shown in a Supplementary Video.
Routine tests and a screening for neurometabolic diseases were 
normal; however, AFP was elevated at 12 µg/L (normal value < 8). 
Albumin, cholesterol, immunoglobulin, and creatine kinase (CK) 
levels were normal. Antibodies against human T-cell lymphotropic 
virus type 1 (HTLV-1) and for paraneoplastic-/autoimmune-medi-
ated ataxias and celiac disease were absent. A second MRI at age 27 
revealed progression of  cerebellar atrophy (Figure 1), and this atro-
phy was moderated and extended into the medial cerebellar 
peduncles.
Mutations for common hereditary ataxias, including FRDA and 
the polyglutamine spinocerebellar ataxias (spinocerebellar ataxia 1, 
2, 3, 6, and 7 and dentatorubropallidoluysian ataxia) were ruled out 
at a different center. Testing for POLG mutations was negative. A 
targeted single-gene genetic test identified the previously described 
pathogenic mutations c.5308_5311del (pGlu1770Ilefs*) and 
c6029A>G (p.Asn2010Ser) in senataxin (SETX).1,2 Each parent har-
bored one of  the heterozygous SETX mutations. The patient was 
subsequently diagnosed with AOA2.
Discussion
The presence of  polyneuropathy and elevated AFP significantly 
narrows the differential diagnosis in patients with early-onset cerebel-
lar ataxia. In this case, a targeted gene analysis was justified. AOA2 is, 
after FRDA, the second most common genetic ataxia in some parts of  
Europe.3 Furthermore, AOA2 is panethnic with clusters occurring in 
some areas, such as Quebec.3,4 Age of  onset (AO) is usually during 
puberty (median 14 years) and the disease is slowly progressive.2–8 
Anheim et al. found that AO in AOA2 correlates with disease duration 
(DD).2 Despite its name, OMA is not a universal trait in AOA2 or 
ataxia-telangiectasia (A-T); OMA occurred in ~50% and strabismus 
in ~12% of  patients with AOA2 in the largest cohort analyzed to date 
(90 patients).2 In contrast, OMA was absent but strabismus found in 
30% of  patients in a French-Canadian cohort.4 OMA is more com-
mon in AOA1 and ataxia with oculomotor apraxia 4 (AOA4) but both 
conditions have earlier AO (<10 years) than AOA2.2,5 A thorough 
study using video-oculography (VO) could not distinguish AOA2 from 
A-T or AOA1.9 On the other hand, strabismus can precede ataxia and 
its presence is highly suggestive of  AOA2.2,3 In addition, early AO in 
AOA2 is associated with a higher frequency of  strabismus.2 Corrective 
surgery for strabismus in our case had only transient benefit, but there 
is no systematic evaluation of  this treatment in patients with AOAs 
and A-T.
Hyperkinesias, such as dystonia, myoclonus, or chorea, are common 
in AOA1 but more variable in AOA2. In contrast to AOA1 and the 
classic form of  A-T, cognition is usually unaffected in AOA2.3 Pyramidal 
signs occur in ~20% of  patients with AOA22 but were absent in the case 
we describe here.
Cerebellar atrophy is very common if  not a universal trait in AOA2 
ranging from 96 to 100%.2–4,7,8 In the patient, we describe cerebellar 
atrophy that was progressively more pronounced in the vermis. A sim-
ilar high frequency of  axonal polyneuropathy has been demonstrated 
in different cohorts.2–4,6–8 Of  note, the underlying polyneuropathy is 
similar in AOA1, AOA2, AOA4 and A-T which illustrates the impor-
tance of  determining albumin, cholesterol, and immunoglobulin lev-
els. Hypoalbuminemia and hypercholesterolemia with normal AFP 
are the hallmarks of  AOA1.10 Immunoglobulin levels are usually 
reduced in A-T. In this context, the degree of  AFP elevation is a more 
useful diagnostic clue to distinguish AOA2 and A-T with higher levels 
Figure 1. Neuroimaging in AOA2. Midsagittal T1-weigthed brain MRI of  
the patient at age 27 showing moderate cerebellar atrophy and enlarged interfo-
lial spaces.
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(tenfold elevation) seen in the latter condition. However, 5% of  
patients with A-T have normal AFP levels.3 Elevation of  AFP is pro-
gressive in A-T but mild and stable over the course of  disease for 
AOA2.2,11 Importantly, AFP elevation is an almost universal feature of  
AOA2 (present in 99–100%) but it does not correlate with DD or dis-
ease severity in AOA2, preventing its use as a disease biomarker.2,4,8 
AFP is still a very useful diagnostic tool for A-T and AOA2,12,13 
although sometimes repeated measurements are required before ele-
vated levels can be established.2 Other clinical clues favoring AOA2 
are the lack of  immunodeficiency, pulmonary symptoms, and family 
history of  cancer. All these features and increased sensitivity to ioniz-
ing radiation are hallmarks of  A-T. In addition, various endocrine 
abnormalities affect patients with A-T, whereas POF or hypogonad-
ism affects some patients with AOA2.2,6,14 Furthermore, infertility has 
recently been reported in patients with AOA2.15 Obesity has been 
described in one-third of  patients with AOA4 but not in AOA2 or 
A-T.16,17 In addition, some patients with AOA4 display elevated AFP 
(1.5–4-fold) but the majority have hypercholesterolemia and hypoal-
buminemia.16,17 AFP is also elevated in patients from the only family 
diagnosed with ataxia with oculomotor apraxia type 3 (AOA3) and 
very rarely in AOA1.17,18 Few reports have described elevated AFP in 
mitochondrial depletion syndromes but longitudinal studies assessing 
AFP levels are lacking.19–21 Some patients with AOA2 also have ele-
vated CK levels, mild hypoalbuminemia, or hypercholesterolemia. 
AFP is also elevated in germinal tumors potentially linking ataxia to 
paraneoplastic cerebellar degeneration (PCD). However, since PCD is 
usually associated with subacute onset and rapid progression, it was 
not part of  the differential diagnosis in our case. In contrast to classic 
A-T, patients with AOA2 may survive to old age, but variable degree 
of  hyperkinesias occurs in both conditions more commonly in A-T.2,3 
Moreover, variant ataxia-telangiectasia (vA-T) is sometimes associated 
with generalized dystonia and absence of  ataxia illustrating the wide 
phenotypic variability in the spectrum of  mutations in the ataxia- 
telangiectasia mutated (ATM ) gene.22–26
SETX encodes for a DNA/RNA helicase with multiple functions 
including maintenance of  genomic stability, DNA damage response 
(DDR), transcription termination, RNA metabolism, and neurogene-
sis.27 Evidence in a yeast homolog, Sen 1, indicates that it prevents accu-
mulation of  RNA/DNA hybrids (R-loops) formed during transcription. 
An abnormal accumulation of  R-loops may play a role in neurodegen-
eration caused by mutated RNA-associated proteins such as ataxin-2.27 
Of  note, heterozygous SETX mutations are also associated with juvenile 
motor neuron disease, amyotrophic lateral sclerosis 4 (ALS4), and 
tremor.28,29 Anheim et al. found that missense mutations in the helicase 
domain of  SETX were associated with a less severe AOA2 presentation 
than mutations outside of  this domain or truncating mutations.2 Indeed, 
one of  the mutations (p.Asn2010Ser) in our case is located in the heli-
case domain (C-terminal) and may result in expression of  mutant sena-
taxin contributing to a milder phenotype. It has been proposed that 
SETX mutations associated with ALS4 are gain-of-function.2,30 Although 
the mechanism linking AOA2, A-T, and AOA4 with elevated AFP is still 
unknown, disrupted regulation of  AFP expression has been suggested.30 
Neither the knockout mouse models for SETX nor AFP feature neurolog-
ical abnormalities, despite replicating the reproductive and molecular 
abnormalities found in patients, adding more complexity to the disease 
mechanism.30 In contrast to the aforementioned ataxia diseases, AFP 
levels are reduced in Down’s syndrome.13
AFP is highly expressed during normal fetal development; this 
expression declines after birth and reaches stable (adult) levels around 
age 2 years. Of  note, some patients have a genetic AFP deficiency and 
some are predisposed to elevated levels without any pathological associ-
ation.13 Nonneurological conditions with elevated AFP include hepato-
cellular carcinoma, hepatitis, congenital hypothyroidism, and fetal 
malformations; in the past, fetal malformations were screened by ana-
lyzing maternal AFP serum levels during pregnancy.13
Etiological diagnosis for ataxias is crucial for proper management, 
prognosis, genetic counseling, and hopefully for future pharmacological 
trials. Treatment for AOA2 and similar disorders is largely symptomatic, 
and current efforts in basic research will hopefully translate into disease 
modifying therapies. A-T and the other conditions in the spectrum of  
ATM mutations are in this context systemic syndromes with radiosensi-
tivity, increased risk for malignancy, severe pulmonary disease, and 
reduced life expectancy. So far there is no evidence for malignancy in 
AOA2 despite SETX being involved in DDR.
Current guidelines recommend testing patients with young-onset 
ataxia for FRDA31 even in settings with low prevalence for FRDA such 
as Scandinavia.32 In the context of  ataxia with or without strabismus, 
polyneuropathy, and mild to moderate elevated AFP, it is reasonable to 
perform a targeted test for AOA2 as in the case we have described. 
Increasing accessibility, faster turnaround, and lower costs make either 
whole exome or genome sequencing reasonable options when AOA2 is 
hard to discern from its differential diagnosis. However, an important 
limitation of  next-generation sequencing is that they do not detect 
pathological polynucleotide expansions.
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